肺癌是治疗效果最差的实体癌之一。常首选外科治疗,手术治疗效果较恒定,术后五年生存率为30—40%。黄氏报告576例肺癌术后远期效果,五年生存率为43.4%。肺癌一旦确诊,多数已为晚期,能够进行手术的不超过30—40%。术后患者常有微小转移灶出现,单用外科疗法完全治愈的很少,小细胞癌早期亦常不宜手术,所以化学治疗对肺癌来说也很必要。林氏报告210例肺癌手术治疗效果,其中4/5的患者进行了化疗,三年生存率为61.1%,五年生存率为53.3%。近年来,肺癌的化学治疗效果有很大提高,越来越多的人已经不再把化疗当作姑息疗法,而正在向根治过渡。化疗已从单用向联合应用,小剂量连续应用向大剂量间歇应用变更。现代化疗以大剂量间歇疗法为主流。本文就联合化疗的药物选择,常用方案及注意事项介绍如下。 Lung cancer is one of the worst solid cancers. Surgical treatment is often preferred. The surgical treatment is more stable and the 5-year survival rate is 30-40%. Huang reported the long-term effect of 576 lung cancer patients after surgery, with a five-year survival rate of 43.4%. Once lung cancer is diagnosed, most have been advanced and no more than 30-40% of the patients can undergo surgery. Patients often have small metastatic lesions after surgery. They are rarely cured with surgical therapy alone. Small cell carcinoma is often not suitable for early surgery. Therefore, chemotherapy is also necessary for lung cancer. Lin reported 210 cases of surgical treatment of lung cancer, of which 4/5 patients had undergone chemotherapy. The three-year survival rate was 61.1%, and the five-year survival rate was 53.3%. In recent years, the effect of chemotherapy on lung cancer has been greatly improved, and more and more people are no longer treating chemotherapy as palliative, but are transitioning to cure. Chemotherapy has changed from single use to combined use, with small doses continuously applied to high dose intermittent applications. Modern chemotherapy is dominated by high-dose intermittent therapy. This article describes the drug selection, common protocols, and precautions for combination chemotherapy.